ISSN: 2278-0238

Revista Internacional de Pesquisa e Desenvolvimento em Farmácia e Ciências da Vida

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Abstrato

Unlocking Novel Therapies: Drug Discovery through Pharmacoinformatics

Dr. Mika Adinath

In the dynamic landscape of drug discovery, where innovation and efficiency are paramount, the integration of advanced technologies has revolutionized the process. One such game-changer is Pharmacoinformatics-a discipline that harnesses the power of computational methods and data analysis to expedite the identification and development of new therapeutic agents. In this article, we delve into the world of drug discovery through pharmacoinformatics, exploring its significance, methodologies, and the transformative impact it holds for the pharmaceutical industry.

The conundrum of traditional drug discovery: Historically, drug discovery was a time-consuming and resource-intensive process involving countless experiments and screenings of chemical compounds. However, pharmacoinformatics emerged as a solution to this challenge, leveraging computational approaches to streamline drug discovery pipelines and enhance the probability of success.

Pharmacoinformatics unveiled pharmacoinformatics is the intersection of pharmacology, chemistry, and computer science. It encompasses a range of computational techniques aimed at accelerating various stages of drug discovery, from target identification and compound screening to optimization and clinical trials.

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado.